Table 1 Fidaxomicin utilization rates
From: A multi-center study of fidaxomicin use for Clostridium difficile infection
2011 Quarters 3 and 4 | 2012 Quarters 1 and 2 | 2012 Quarters 3 and 4 | 2013 Quarters 1 and 2 | Overall time period | |
|---|---|---|---|---|---|
Fidaxomicin utilization from third quarter of 2011 to second quarter of 2013 | |||||
Number of CDI patients | 5098 | 5582 | 5160 | 6084 | 21,924 |
Number of patients who received FDX | 11 | 119 | 126 | 218 | 474 |
FDX use rate | 0.22 % | 2.1 % | 2.4 % | 3.6 % | 2.16 % |
West | Mid-West | South | Northeast | |
|---|---|---|---|---|
Fidaxomicin utilization rates stratified by regions in the United States | ||||
Number of CDI patients per region | 3143 | 5050 | 9026 | 4705 |
Number of patients who received FDX per region | 79 | 105 | 200 | 90 |
Overall FDX use rates per region* | 2.51 % | 2.08 % | 2.21 % | 1.91 % |
Hospital location | Hospital type | |||
|---|---|---|---|---|
Rural | Urban | Teaching hospitals | Non-teaching hospitals | |
Fidaxomicin utilization rates stratified by hospital location or hospital type | ||||
Number of CDI patients per hospital location or type | 2577 | 19,347 | 9304 | 12,620 |
Number of patients who received FDX per hospital location or type | 38 | 436 | 187 | 287 |
Overall FDX use rates per hospital location or type* | 1.47 % | 2.25 %** | 2 % | 2.27 %^ |